In fact, these observations instigated the testing of pharmacological inhibitors of RIPK1 in pancreatic cancer patients (with or without combination with anti-PD1 immunotherapy) with the aim to ameliorate the immunosuppressive tumor milieu [224]. This evidence concerns the gene RIPK1 and neoplasm.